A practical reference on Incretin hormone: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
Tirzepatide is a synthetic peptide of 39 amino acids that carries a C20 fatty diacid side chain attached through a linker. Its molecular formula is C225H348N48O68, and its molecular weight is about 4813 daltons. The compound belongs to the incretin mimetic class and is administered by subcutaneous injection. The fatty acid chain promotes binding to serum albumin, which slows renal clearance and extends the circulation time of the molecule. It was identified during screening of sequences derived from glucose-dependent insulinotropic polypeptide.
Tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor, making it a dual agonist rather than a selective agent. Engagement of the GLP-1 receptor is linked to glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. The relative contribution of the GIP arm remains an active research question; proposed roles include improved insulin sensitivity and altered adipose tissue handling. Receptor occupancy studies suggest the molecule interacts with both targets at circulating concentrations achieved during therapy.
Development began in the 2010s, when researchers modified a GIP-based scaffold to add GLP-1 activity and then attached the fatty diacid to lengthen its half-life. Clinical evaluation proceeded through large phase 3 programmes in type 2 diabetes and in obesity, and regulators in the United States cleared the compound for type 2 diabetes in 2022 and for chronic weight management in 2023. Several cardiovascular and metabolic outcome studies are still reporting, so the picture of long-term benefit and risk is incomplete. Approvals in other regions followed on different timelines.
The GIP receptor is expressed in pancreatic islets, adipose tissue, and the central nervous system, while GLP-1 receptors are found in pancreatic islets, the gastrointestinal tract, and the brain. Activation of both receptors can enhance glucose-dependent insulin secretion and reduce glucagon release. The relative contribution of each receptor to the overall pharmacological effect remains an area of ongoing investigation. Preclinical studies suggest that GIP receptor agonism may modulate appetite and energy balance, but the precise mechanisms in humans are not fully established.
In clinical research, tirzepatide has been studied in randomized controlled trials for glycemic control and body weight reduction. These trials typically measure changes in hemoglobin A1c and body weight over periods of several months. The drug is administered by subcutaneous injection, and its pharmacokinetic profile supports once-weekly dosing. Post-marketing surveillance continues to evaluate long-term outcomes and rare adverse events.
Tirzepatide is a synthetic peptide that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The molecule contains 39 amino acids and features a C20 fatty diacid moiety attached via a linker, which promotes albumin binding and extends its circulating half-life. Its sequence incorporates non-natural amino acids and modifications that reduce susceptibility to degradation by dipeptidyl peptidase-4. This dual receptor activity distinguishes it from selective GLP-1 receptor agonists.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C225H348N48O68 | Peptide backbone with a fatty diacid chain |
| Molecular weight | About 4813 Da | Calculated from the formula |
| Receptor targets | GIP and GLP-1 receptors | Dual agonist activity at both sites |
| Route of administration | Subcutaneous injection | No approved oral form at present |
| Elimination half-life | About 5 days | Supports extended intervals between administrations |
An extended fatty diacid moiety promotes binding to serum albumin, which slows renal clearance and extends the circulating half-life to roughly five days. That property supports once-weekly administration and largely explains the dosing interval described in clinical reports. Published data come mainly from large randomised programmes that evaluated glycaemic control and body weight over periods of many months. Long-term outcomes beyond those trial windows, including what happens after treatment stops, remain an active area of investigation.
Tirzepatide is a synthetic peptide built from thirty-nine amino acids. Its sequence is derived from native glucose-dependent insulinotropic polypeptide, or GIP, with several non-natural residues and a fatty diacid side chain attached through a linker. The molecule behaves as a dual agonist at two incretin receptors, GIP and GLP-1, instead of targeting a single receptor. This dual engagement separates it from earlier single-receptor incretin compounds and underpins most of its reported pharmacological activity.
At the receptor level, the compound binds both GIP and GLP-1 receptors and triggers downstream signalling that raises cyclic AMP in target cells. GLP-1 receptor activation is associated with glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. GIP receptor activation contributes effects that are less completely characterised, and how much each receptor adds to the overall clinical response is still an open question. The two pathways appear to interact in a complementary rather than a purely additive way.
Receptor activation by tirzepatide raises intracellular cyclic AMP through Gs-coupled signalling at both targets. At the GLP-1 receptor the downstream effect includes glucose-dependent insulin release, suppressed glucagon secretion, delayed gastric emptying, and reduced appetite signalling in the hypothalamus. GIP receptor engagement adds insulinotropic activity and appears to influence lipid handling in adipose tissue. Because both receptors are stimulated at the same time, the pharmacological profile differs from that of selective GLP-1 receptor agonists, and the relative contribution of each arm remains an area of active investigation.
Clinical development proceeded through large phase 3 programmes in type 2 diabetes and in obesity or overweight with at least one weight-related comorbidity. Regulatory approvals followed in several jurisdictions for both indications. Weekly subcutaneous dosing reflects an elimination half-life of roughly five days. Open questions include the durability of metabolic effects after treatment stops, long-term cardiovascular and hepatic outcomes beyond completed trials, and whether the dual mechanism confers benefits independent of total receptor occupancy. Published literature continues to expand on these points. Substantial uncertainty remains about interindividual variability in response.
== Music and lyrics == Guitarist-vocalist Bill Steer retrospectively said that "The first album wasn’t very focused, it was just about being fast and heavy..." He went on to say that the band did not intend the muddy sound present throughout the album: "The first one obviously is a crazy accident. It’s got a small following but we did not intend to make that record the thing that people hear now. We had different ideas and we just couldn’t execute them. We were too young, too naïve, and inexperienced. From 'Symphonies' onwards, we got better at achieving the things we wanted to achieve in the studio." Revolver said that the album's music was "hectic, brutal and sounds like it was recorded beneath a stack of wet mattresses." Invisible Oranges wrote: "Carcass’ 1988 [debut] set new standards for auditory dismemberment, channeling the sound of Napalm Death through a vomited, gore-encrusted wormhole backwards. This is the aural nightmare of the dissecting table pushed beyond the extremes previously explored by the tinny sounds of blackthrash with bowl-rupturing, gurgling low end. Ken Owen flails about so nightmarishly you can’t even really distinguish if he’s even playing drums or has merely taken the contents of mortician’s tools of the trade and thrown them out of the window of morgue into the biohazard-labeled dumpster." Lyrical themes explored on the album include vomitting, feces, wound healing, and foeticide. According to Revolver, the track "Foeticide" is a "horrific description of abortion by electrocution [...] a mad scientist frying human babies in their wombs."
The enzyme is believed to act on the so-called "quinonoid" form of the starting dihydrobiopterin. This is in contrast to the enzyme dihydrofolate reductase, which normally acts on dihydrofolic acid but can also reduce the isomer, L-erythro-7,8-dihydrobiopterin.
The Romanian revolution (Romanian: Revoluția română) was a period of violent civil unrest in the Socialist Republic of Romania during December 1989 as a part of the revolutions of 1989 that occurred in several countries around the world, primarily within the Eastern Bloc. The Romanian revolution started in the city of Timișoara and soon spread throughout the country, ultimately culminating in the drumhead trial and execution of longtime Romanian Communist Party (PCR) General Secretary Nicolae Ceaușescu and his wife Elena, and the end of 42 years of Communist rule in Romania. It was also the last removal of a Marxist–Leninist government in a Warsaw Pact country during the events of 1989, and the only one that violently overthrew a country's leadership and executed its leader; according to estimates, over one thousand people died and thousands more were injured. Following World War II, Romania found itself inside the Soviet sphere of influence, with Communist rule officially declared in 1947. In April 1964, when Romania published a general policy paper worked out under Gheorghe Gheorghiu-Dej's instructions, the country was well on its way of carefully breaking away from Soviet control. Nicolae Ceaușescu became the country's leader the following year. Under his rule, Romania experienced a brief waning of internal repression that led to a positive image both at home and in the West. However, repression again intensified by the 1970s, and Ceaușescu's regime eventually became one of the most repressive in the world and one of the most repressive of modern times.
Glucose is a sugar with the molecular formula C6H12O6. It is the most abundant monosaccharide, a subcategory of carbohydrates. It is made from water and carbon dioxide during photosynthesis by plants and most algae. It is used by plants to make cellulose, the most abundant carbohydrate in the world, for use in cell walls, and by all living organisms to make adenosine triphosphate (ATP), which is used by the cell as energy. Glucose is often abbreviated as Glc. In energy metabolism, glucose is the most important source of energy in all organisms. Glucose for metabolism is stored as a polymer, in plants mainly as amylose and amylopectin, and in animals as glycogen. Glucose circulates in the blood of animals as blood sugar. The naturally occurring form is d-glucose, while its stereoisomer l-glucose is produced synthetically in comparatively small amounts and is less biologically active. Glucose is a monosaccharide containing six carbon atoms and an aldehyde group, and is therefore an aldohexose. The glucose molecule can exist in an open-chain (acyclic) as well as ring (cyclic) form. Glucose is naturally occurring and is found in its free state in fruits and other parts of plants. In animals, it is released from the breakdown of glycogen in a process known as glycogenolysis. Glucose, as intravenous sugar solution, is on the World Health Organization's List of Essential Medicines. It is also on the list in combination with sodium chloride (table salt). The name glucose is derived from Ancient Greek γλεῦκος (gleûkos) 'wine, must', from γλυκύς (glykýs) 'sweet'.
Sources: en.wikipedia.org
Leucine is a branched-chain amino acid (BCAA) since it possesses an aliphatic side chain that is not linear. Racemic leucine had been subjected to circularly polarized synchrotron radiation to better understand the origin of biomolecular asymmetry. An enantiomeric enhancement of 2.6% had been induced, indicating a possible photochemical origin of biomolecules' homochirality.
Armstrong acid (naphthalene-1,5-disulfonic acid) is a fluorescent organic compound with the formula C10H6(SO3H)2. It is one of several isomers of naphthalenedisulfonic acid. It a colorless solid, typically obtained as the tetrahydrate. Like other sulfonic acids, it is a strong acid. It is named for British chemist Henry Edward Armstrong.
Traditional additive solutions are hypotonic, although experiments with next-generation additive solutions suggest that an alkali pH in combination with low chloride concentrations may be able to prolong the red blood cell viability. Leucocyte depletion of blood components, including red blood cell concentrates, is increasingly becoming standard practise; in many of the high-income countries of the world, 100% of the red blood cell supply is already being leucocyte depleted. Leucocyte depletion, usually by a leucocyte filter included in the blood bag system, is an efficient yet relatively cheap way of reducing the risk of transfusion reactions. Leucocyte depletion is most commonly performed as an integrated processing step, as bedside filtration is considered a less efficient method.
In a scientific research study or clinical trial, a flaw in the study design or the method of collecting or interpreting information. Biases can lead to incorrect conclusions about what the study or clinical trial showed. (NCI) When a point of view prevents impartial judgment on issues relating to the subject of that point of view. In clinical studies, bias is controlled by blinding and randomization (NLM) The systematic tendency of any factors associated with the design, conduct, analysis and evaluation of the results of a clinical trial to make the estimate of a treatment effect deviate from its true value. Bias introduced through deviations in conduct is referred to as 'operational' bias. The other sources of bias listed above are referred to as 'statistical'. (ICH E9) Bioavailable
Glycine max subsp. formosana (Hosok.) Tateishi & H.Ohashi Glycine max nothosubsp. gracilis (Skvortsov) H.Ohashi = G. max subsp. max × G. max subsp. soja Glycine max subsp. max Glycine max subsp. soja (Siebold & Zucc.) H.Ohashi
Sources: en.wikipedia.org
Banasiewicz, Bill (1988). Rush: Visions: The Official Biography. Omnibus Press. ISBN 0-7119-1162-2. Daly, Skip; Hansen, Eric (2019). Rush: Wandering the Face of the Earth – The Official Touring History. Insight Editions. ISBN 978-1-68383-450-2. Popoff, Martin (2004). Contents Under Pressure: 30 Years of Rush at Home and Away. ECW Press. ISBN 978-1-550-22678-2. Marsh, Dave (1979). The Rolling Stone Record Guide : reviews and ratings of almost 10,000 currently available rock, pop, soul, country, blues, jazz, and gospel albums (1st ed.). New York: Random House. ISBN 0-394-41096-3.
=== Diagnostic criteria === An international group created a set of criteria for the diagnosis of primary Sjögren's disease in 2016 based on consensus around previous guidelines from the American College of Rheumatology (ACR) and European League Against Rheumatism (EULAR), which became known as the ACR-EULAR criteria. Although used primarily for recruitment into clinical trials, the criteria were shown to be effective in diagnosing Sjögren's by a 2025 Swedish cohort study. Per the ACR-EULAR criteria, a person with previously reported dry eye or dry mouth symptoms (including if responding positively to a short questionnaire) has SjD if they have a score of at least 4 when considering the following items:
== Treatment == Disease progression may be slowed with immunosuppressives and other medications, and esophageal reflux, pulmonary hypertension and Raynaud phenomenon may benefit from symptomatic treatment. However, there is no cure for this disease as there is no cure for scleroderma in general.
== Further reading == Oliver, Brian; Devitt, Catherine; Park, Grace; Razak, Alina; Liu, Sun Mei; Bergese, Sergio D. (2025). "Drugs in Development to Manage Acute Pain". Drugs. 85 (1): 11–19. doi:10.1007/s40265-024-02118-0. PMID 39560856. Broadfoot, Marla (20 August 2024). "New Painkiller Could Bring Relief to Millions—Without Addiction Risk". Scientific American. Archived from the original on 30 December 2024. Retrieved 20 July 2026.
Sources: en.wikipedia.org
It is a synthetic 39-amino-acid peptide that acts on two incretin receptors, the GIP receptor and the GLP-1 receptor. It is given by subcutaneous injection and has a circulating half-life of roughly five days. It is not a small molecule and is not absorbed usefully from the gut in conventional oral form.
Selective agents act on one receptor, while tirzepatide engages both GIP and GLP-1 receptors. The added GIP activity may contribute effects on insulin sensitivity and on fat metabolism. Whether the dual action produces meaningful clinical advantages beyond differences in potency is still being examined.
The downstream consequences of GIP receptor activation are not fully characterised in humans. It is also unclear how much each receptor contributes to appetite reduction and to shifts in body composition. Published work describes associations and proposed pathways rather than settled causal chains.
It activates both GIP and GLP-1 receptors. This dual action differentiates it from selective GLP-1 agonists.